Add to ORKGCurrent efforts to foster research on orphan diseases are focused largely on pharmaceutical treatments. Currently, there are roughly 770 FDA approved pharmaceutical treatments designated for orphan diseases. The number of treatments has greatly improved and it can largely be attributed to government efforts to foster research on orphan diseases. However, more can be done to bridge the gap between the number of available treatments, both pharmaceutical and non-pharmaceutical, and the number of different orphan diseases. These efforts should be supplemented by initiatives to bolster diffusion and commercialization of innovations made by the user-innovator community
Since the early 80s, orphan drug regulations have been introduced to stimulate R&D for rare dise...
The Orphan Drug Act is a statute with a noble purpose but a controversial history. Originally design...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
Current efforts to foster research on orphan diseases are focused largely on pharmaceutical treatmen...
Orphan diseases pose both a challenge to the global medical community and an opportunity for it to f...
The World Health Organization defines orphan diseases, as all pathological conditions, affecting 0....
Collaborations between for-profit drug companies and not-for-profit disease advocacy groups have ris...
Cette contribution analyse les formes de militantisme politique et scientifique qui ont émergé autour...
In the U.S., a rare disease is one that affects fewer than 200,000 patients. There are more than 7,0...
Background The Orphan Drug Act (1983) established several incentives to encourage the development...
Background More than 6,800 rare diseases and conditions have been identified in the US, which affect...
On the thirty-fifth anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormo...
© 2017 About 7000 rare, or orphan, diseases affect more than 350 million people worldwide. Although ...
Through the combined efforts of agencies and organizations in the public and private sector, drugs h...
Since the early 80s, orphan drug regulations have been introduced to stimulate R&D for rare dis...
Since the early 80s, orphan drug regulations have been introduced to stimulate R&D for rare dise...
The Orphan Drug Act is a statute with a noble purpose but a controversial history. Originally design...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
Current efforts to foster research on orphan diseases are focused largely on pharmaceutical treatmen...
Orphan diseases pose both a challenge to the global medical community and an opportunity for it to f...
The World Health Organization defines orphan diseases, as all pathological conditions, affecting 0....
Collaborations between for-profit drug companies and not-for-profit disease advocacy groups have ris...
Cette contribution analyse les formes de militantisme politique et scientifique qui ont émergé autour...
In the U.S., a rare disease is one that affects fewer than 200,000 patients. There are more than 7,0...
Background The Orphan Drug Act (1983) established several incentives to encourage the development...
Background More than 6,800 rare diseases and conditions have been identified in the US, which affect...
On the thirty-fifth anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormo...
© 2017 About 7000 rare, or orphan, diseases affect more than 350 million people worldwide. Although ...
Through the combined efforts of agencies and organizations in the public and private sector, drugs h...
Since the early 80s, orphan drug regulations have been introduced to stimulate R&D for rare dis...
Since the early 80s, orphan drug regulations have been introduced to stimulate R&D for rare dise...
The Orphan Drug Act is a statute with a noble purpose but a controversial history. Originally design...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...